NEW DELHI — Managing diabetes in India just became significantly easier for millions of adults. Danish pharmaceutical giant Novo Nordisk officially launched its revolutionary medication, Awiqli, on Thursday, July 9, 2026. This product is the world’s first once-weekly basal insulin injection approved for clinical use.
Consequently, patients can now replace their exhausting daily injection routines with a single weekly dose. This massive medical advancement transforms traditional diabetes care. It effectively reduces the annual injection burden from 365 painful pricks down to just 52.
Great news for diabetes patients in India! Novo Nordisk has officially launched Awiqli, a groundbreaking once-weekly basal insulin injection. Say goodbye to daily pricks and enjoy better blood sugar control for just ₹261 per week.
Read the full story here :…— India This Week (@indiathisweekk) July 10, 2026
A Crucial Milestone for India’s Diabetes Crisis
India currently faces an unprecedented metabolic health emergency. According to recent data from the ICMR-INDIAB study, over 101 million people live with diabetes across the nation. Furthermore, another 136 million individuals suffer from prediabetes. These staggering numbers highlight a massive public health challenge.
Also Read : Meta AI Glasses Could Bring Super-Sensing Features with…
Historically, many Indian patients delay vital insulin therapy by seven to nine years. This dangerous delay happens because people dread the physical pain of daily needles. Additionally, complex routines and financial fears cause widespread treatment hesitation.
The innovative once-weekly basal insulin injection directly eliminates these deep psychological barriers. By simplifying the treatment process, medical experts believe patient compliance will improve dramatically. Patients will no longer view insulin as an overwhelming daily punishment. Instead, they will see it as a manageable weekly routine.
Superior Blood Sugar Control Without Added Risks
Awiqli contains a long-acting formula known scientifically as insulin icodec. This specialized molecule binds efficiently to albumin proteins in the human bloodstream. Therefore, the drug releases very slowly and works steadily over seven full days.
The global ONWARDS Phase 3 clinical trials proved the drug’s incredible real-world effectiveness. These extensive medical studies included numerous active participants from India. The clinical data revealed excellent results.
- Better HbA1c Reduction: Awiqli achieved superior long-term blood sugar reduction compared to daily insulin glargine U100.
- Increased Time in Range: Patients spent significantly more hours of the day in a healthy blood glucose zone.
- Comparable Safety Profile: The weekly injection did not increase the risky instances of low blood sugar, known as hypoglycaemia.
Therefore, patients achieve superior glycemic control without compromising their safety. It offers an effective, scientifically proven treatment alternative.
Competitive Pricing Strategy Shocks the Medical Market
Medical costs remain a primary concern for most Indian households. Surprisingly, Novo Nordisk introduced this medication at a highly competitive price point. This strategic pricing structure makes the modern innovation accessible to ordinary citizens.
A standard weekly dose of 70 insulin units costs exactly ₹261. In comparison, traditional once-daily basal insulin products cost between ₹345 and ₹453 for the same amount. Consequently, this new weekly alternative saves patients money while offering unmatched lifestyle convenience.
The medicine will hit pharmacies nationwide through an established network of 45,000 distributors. It comes in convenient, pre-filled FlexTouch pen devices. The company sells a 1 ml pen containing 700 units for ₹2,611. Additionally, a larger 3 ml pen containing 2,100 units costs ₹7,833. A single 1 ml pen can easily last an average patient ten weeks.
What Leading Endocrinologists Say About the Launch
Medical professionals across India welcome this change enthusiastically. Dr. S.K. Wangnoo, a senior consultant endocrinologist at Indraprastha Apollo Hospitals in New Delhi, shared his professional insights during the launch. He emphasized that poor treatment adherence constantly undermines positive patient outcomes.
“Innovations that meaningfully simplify the treatment experience have the potential to change patient behavior,” Dr. Wangnoo stated. He noted that a once-weekly basal insulin injection removes the deep apprehension surrounding treatment. Doctors can now hold more productive conversations with hesitant patients.
Vikrant Shrotriya, the Managing Director of Novo Nordisk India, expressed immense pride in this historic milestone. He stated that making insulin simpler has been a century-long goal. Today, that ambitious dream is a concrete reality for Indian citizens. India is notably the seventh country globally to welcome this premium therapy.
Shaping the Future of Indian Healthcare
The domestic insulin market in India is expanding rapidly due to shifting modern lifestyles. Financial experts project the market will grow from $660.5 million in 2025 to $916.4 million by 2034. Currently, only 6 million Indians use insulin therapy regularly. Novo Nordisk expects this number to rise to 9 million quickly.
Awiqli will face healthy competition from established daily brands like Sanofi’s Lantus. Furthermore, local pharmaceutical companies like Biocon, Lupin, and Eris Lifesciences offer affordable generic glargine alternatives. However, the unique once-weekly dosing advantage gives Awiqli a distinct competitive edge. This product will undoubtedly redefine modern standards for diabetes care in India.